TP53 and lung cancer: A prominent example is their inhibition of the PI3K/Akt pathway—GA treatment in lung cancer cells led to downregulation of PI3K/Akt alongside increased p53 levels, which in turn activated downstream executioner caspases and cell cycle inhibitors (p21Cip1/p27Kip1), culminating in apoptosis and growth arrest (151).